REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome

NCT06914609 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Angelman Syndrome

Interventions

DRUG: ION582
DRUG: Placebo

Sponsor

Ionis Pharmaceuticals, Inc.